| Market Capitalization (Millions $) |
145 |
| Shares
Outstanding (Millions) |
5 |
| Employees |
102 |
| Revenues (TTM) (Millions $) |
33 |
| Net Income (TTM) (Millions $) |
-70 |
| Cash Flow (TTM) (Millions $) |
-22 |
| Capital Exp. (TTM) (Millions $) |
0 |
Business Description
Mersana Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing antibody-drug conjugates (ADCs) for the treatment of various types of cancer. Based in Cambridge, Massachusetts, the company's platform technology, called Dolaflexin, uses a proprietary linker and payloads to create targeted therapies that selectively deliver potent anticancer agents to tumors.
Mersana's lead product candidate, XMT-1536, is being developed to address a range of tumor types that express the NaPi2b protein, including ovarian cancer, lung cancer, and cancers of the fallopian tube and peritoneum. XMT-1536 has shown promising results in early-stage clinical trials and has received Fast Track designation from the U.S. Food and Drug Administration.
The company has also established partnerships with pharmaceutical companies, including Takeda and Merck, to collaborate on the development and commercialization of ADC therapies. Mersana Therapeutics aims to transform the treatment landscape for cancer patients by harnessing the potential of ADC technology to deliver targeted and more effective therapies.
Company Address: 840 Memorial Drive Cambridge 2139 MA
Company Phone Number: 498-0020 Stock Exchange / Ticker: NASDAQ MRSN
|
19.3% 
100 %